2023
DOI: 10.1016/j.annonc.2023.04.331
|View full text |Cite
|
Sign up to set email alerts
|

P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles